GlassScriptPhysician profile
Sujith Kumar Palleti
NPI 1386215713
$2,895.41
in general payments reported to CMS, 2019-2025
15 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $215 · 2023: $634 · 2024: $892 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,556 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,556.07 |
| Education | $124.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $475.39 | 2023-2025 | Acthar, Terlivaz |
| Astrazeneca Pharmaceuticals LP | $470.35 | 2023-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $388.78 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $341.28 | 2022-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $223.66 | 2022-2025 | Tarpeyo |
| Medtronic, INC. | $206.13 | 2023-2025 | In.Pact Av, In.Pact Admiral, Ellipsys Vascular Access System |
| Novartis Pharmaceuticals Corporation | $173.83 | 2024-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $152.29 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $152.28 | 2022-2025 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $121.25 | 2023-2025 | Ultomiris |
| Daiichi Sankyo INC. | $62.36 | 2023-2024 | Injectafer |
| Amgen INC. | $59.15 | 2022-2025 | Tavneos |
| Nxstage Medical, INC. | $23.50 | 2023 | Nxstage System One |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.11 | 2024 | Jardiance |
| Vifor Pharma, INC. | $22.05 | 2023 | Veltassa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sujith Palleti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.